iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants. The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providing data that is crucial in the fight against the virus. This lab is sequencing the most recent swabs to identify new variants of COVID-19 as the virus continues to progress globally.
"The sequencing of nasal swabs is necessary to determine which variant a patient has tested positive for and provides variant-positive specimens for research," said iSpecimen Founder and CEO, Christopher Ianelli, MD, Ph.D. "Through our relationship with this reference lab, we are able to quickly and efficiently support both commercial and government researchers working day and night to battle COVID-19."
For researchers looking to validate their own variant identification assays, iSpecimen can obtain sequenced and unsequenced COVID-19 positive and negative swabs in a variety of media types. To learn more about COVID-19 specimens at iSpecimen, please visit iSpecimen's website at https://pages.ispecimen.com/COVID-19-Samples.html.
iSpecimen has been working diligently with the research community to understand COVID-19. In early 2020, iSpecimen began sending serum samples to the U.S. Centers for Disease Control and Prevention ("CDC") to help researchers monitor antibody development for possible guidance on immunity. iSpecimen has provided the CDC with 600 SARS-CoV-2-positive serum samples and 100 negative serum samples. In addition, iSpecimen has provided other federal agencies and private companies custom COVID-19 collections, which are often complex and complement the more immediate availability of remnant or banked samples. Overall, iSpecimen has delivered more than 15,000 specimens for more than 200 COVID-related projects since the start of the pandemic.
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.